China Universal Asset Management Co. Ltd. Has $729,000 Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

China Universal Asset Management Co. Ltd. lifted its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 10.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,031 shares of the company’s stock after acquiring an additional 1,273 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Rhythm Pharmaceuticals were worth $729,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. AQR Capital Management LLC raised its holdings in Rhythm Pharmaceuticals by 46.2% in the 2nd quarter. AQR Capital Management LLC now owns 103,830 shares of the company’s stock valued at $4,263,000 after buying an additional 32,831 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Rhythm Pharmaceuticals by 3.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,291 shares of the company’s stock worth $2,024,000 after purchasing an additional 1,667 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of Rhythm Pharmaceuticals by 21.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 19,321 shares of the company’s stock valued at $1,012,000 after buying an additional 3,400 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Rhythm Pharmaceuticals by 26.3% in the third quarter. Exchange Traded Concepts LLC now owns 15,057 shares of the company’s stock valued at $789,000 after buying an additional 3,137 shares during the period. Finally, ORG Wealth Partners LLC acquired a new position in shares of Rhythm Pharmaceuticals in the third quarter worth approximately $63,000.

Insiders Place Their Bets

In related news, insider Pamela J. Cramer sold 4,688 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $65.00, for a total value of $304,720.00. Following the transaction, the insider now directly owns 13,500 shares of the company’s stock, valued at approximately $877,500. The trade was a 25.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer Kayden Lee sold 66,861 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $66.33, for a total transaction of $4,434,890.13. Following the sale, the executive vice president now owns 972 shares of the company’s stock, valued at $64,472.76. This trade represents a 98.57 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,830 shares of company stock valued at $5,622,000. Insiders own 5.60% of the company’s stock.

Rhythm Pharmaceuticals Price Performance

NASDAQ RYTM opened at $59.43 on Friday. The company has a fifty day moving average price of $57.44 and a 200-day moving average price of $52.98. Rhythm Pharmaceuticals, Inc. has a 1 year low of $35.17 and a 1 year high of $68.58. The firm has a market cap of $3.65 billion, a price-to-earnings ratio of -13.73 and a beta of 2.16.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.07. The firm had revenue of $33.20 million during the quarter, compared to analyst estimates of $32.52 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company’s revenue for the quarter was up 47.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.76) EPS. On average, research analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.33 EPS for the current fiscal year.

Analysts Set New Price Targets

RYTM has been the topic of several recent analyst reports. JMP Securities restated a “market outperform” rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Canaccord Genuity Group reissued a “buy” rating and issued a $80.00 price target on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. Bank of America increased their price target on Rhythm Pharmaceuticals from $48.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, October 14th. TD Cowen boosted their target price on shares of Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright restated a “buy” rating and issued a $69.00 price target on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.09.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.